Science 37 Holdings, Inc. (NASDAQ: SNCE) Stock Competitors & Peer Comparison

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, GEHCV has a market cap of 25.5B. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while GEHCV trades at $56.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas GEHCV's P/E ratio is N/A. In terms of profitability, SNCE's ROE is -0.47%, compared to GEHCV's ROE of +0.19%. Regarding short-term risk, SNCE is less volatile compared to GEHCV. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check GEHCV's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, BTSG has a market cap of 11.8B. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while BTSG trades at $60.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas BTSG's P/E ratio is 48.59. In terms of profitability, SNCE's ROE is -0.47%, compared to BTSG's ROE of +0.15%. Regarding short-term risk, SNCE is less volatile compared to BTSG. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check BTSG's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, BTSGU has a market cap of 11.7B. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while BTSGU trades at $198.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas BTSGU's P/E ratio is 179.93. In terms of profitability, SNCE's ROE is -0.47%, compared to BTSGU's ROE of +0.15%. Regarding short-term risk, SNCE is less volatile compared to BTSGU. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check BTSGU's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, TEM has a market cap of 10.9B. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while TEM trades at $61.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas TEM's P/E ratio is -123.88. In terms of profitability, SNCE's ROE is -0.47%, compared to TEM's ROE of -0.55%. Regarding short-term risk, SNCE is less volatile compared to TEM. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check TEM's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, SGFY has a market cap of 8.9B. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while SGFY trades at $30.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas SGFY's P/E ratio is 70.91. In terms of profitability, SNCE's ROE is -0.47%, compared to SGFY's ROE of -0.15%. Regarding short-term risk, SNCE is more volatile compared to SGFY. This indicates higher risk in terms of short-term price fluctuations for SNCE.Check SGFY's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, HQY has a market cap of 8.2B. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while HQY trades at $98.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas HQY's P/E ratio is 23.02. In terms of profitability, SNCE's ROE is -0.47%, compared to HQY's ROE of +0.11%. Regarding short-term risk, SNCE is less volatile compared to HQY. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check HQY's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, TXG has a market cap of 7.8B. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while TXG trades at $61.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas TXG's P/E ratio is -104.49. In terms of profitability, SNCE's ROE is -0.47%, compared to TXG's ROE of -0.09%. Regarding short-term risk, SNCE is less volatile compared to TXG. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check TXG's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, HNGE has a market cap of 7.1B. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while HNGE trades at $91.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas HNGE's P/E ratio is 49.11. In terms of profitability, SNCE's ROE is -0.47%, compared to HNGE's ROE of +0.30%. Regarding short-term risk, SNCE is less volatile compared to HNGE. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check HNGE's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, RCM has a market cap of 6B. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while RCM trades at $14.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas RCM's P/E ratio is -102.21. In terms of profitability, SNCE's ROE is -0.47%, compared to RCM's ROE of +0.00%. Regarding short-term risk, SNCE is more volatile compared to RCM. This indicates higher risk in terms of short-term price fluctuations for SNCE.Check RCM's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, WAY has a market cap of 4.9B. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while WAY trades at $25.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas WAY's P/E ratio is 17.03. In terms of profitability, SNCE's ROE is -0.47%, compared to WAY's ROE of +0.04%. Regarding short-term risk, SNCE is less volatile compared to WAY. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check WAY's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, DOCS has a market cap of 4.9B. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while DOCS trades at $26.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas DOCS's P/E ratio is 17.20. In terms of profitability, SNCE's ROE is -0.47%, compared to DOCS's ROE of +0.17%. Regarding short-term risk, SNCE is less volatile compared to DOCS. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check DOCS's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, HTFL has a market cap of 4.3B. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while HTFL trades at $50.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas HTFL's P/E ratio is -24.88. In terms of profitability, SNCE's ROE is -0.47%, compared to HTFL's ROE of -0.42%. Regarding short-term risk, SNCE is less volatile compared to HTFL. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check HTFL's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, ONEM has a market cap of 3.4B. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while ONEM trades at $16.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas ONEM's P/E ratio is -7.77. In terms of profitability, SNCE's ROE is -0.47%, compared to ONEM's ROE of -0.24%. Regarding short-term risk, SNCE is less volatile compared to ONEM. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check ONEM's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, PRVA has a market cap of 2.6B. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while PRVA trades at $20.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas PRVA's P/E ratio is 98.67. In terms of profitability, SNCE's ROE is -0.47%, compared to PRVA's ROE of +0.00%. Regarding short-term risk, SNCE is less volatile compared to PRVA. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check PRVA's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, NXGN has a market cap of 1.6B. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while NXGN trades at $23.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas NXGN's P/E ratio is -266.00. In terms of profitability, SNCE's ROE is -0.47%, compared to NXGN's ROE of -0.01%. Regarding short-term risk, SNCE is more volatile compared to NXGN. This indicates higher risk in terms of short-term price fluctuations for SNCE.Check NXGN's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, OMCL has a market cap of 1.6B. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while OMCL trades at $34.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas OMCL's P/E ratio is 18.18. In terms of profitability, SNCE's ROE is -0.47%, compared to OMCL's ROE of +0.03%. Regarding short-term risk, SNCE is less volatile compared to OMCL. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check OMCL's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, OMDA has a market cap of 1.4B. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while OMDA trades at $23.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas OMDA's P/E ratio is 333.00. In terms of profitability, SNCE's ROE is -0.47%, compared to OMDA's ROE of +0.02%. Regarding short-term risk, SNCE is less volatile compared to OMDA. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check OMDA's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, AGTI has a market cap of 1.4B. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while AGTI trades at $10.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas AGTI's P/E ratio is -71.79. In terms of profitability, SNCE's ROE is -0.47%, compared to AGTI's ROE of -0.02%. Regarding short-term risk, SNCE is less volatile compared to AGTI. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check AGTI's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, CERT has a market cap of 1.3B. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while CERT trades at $8.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas CERT's P/E ratio is 20.70. In terms of profitability, SNCE's ROE is -0.47%, compared to CERT's ROE of -0.07%. Regarding short-term risk, SNCE is less volatile compared to CERT. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check CERT's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, GDRX has a market cap of 1.2B. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while GDRX trades at $3.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas GDRX's P/E ratio is 10.78. In terms of profitability, SNCE's ROE is -0.47%, compared to GDRX's ROE of +0.03%. Regarding short-term risk, SNCE is less volatile compared to GDRX. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check GDRX's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, TDOC has a market cap of 1.2B. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while TDOC trades at $6.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas TDOC's P/E ratio is -6.52. In terms of profitability, SNCE's ROE is -0.47%, compared to TDOC's ROE of -0.13%. Regarding short-term risk, SNCE is less volatile compared to TDOC. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check TDOC's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, HSTM has a market cap of 869.7M. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while HSTM trades at $29.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas HSTM's P/E ratio is 41.35. In terms of profitability, SNCE's ROE is -0.47%, compared to HSTM's ROE of +0.06%. Regarding short-term risk, SNCE is less volatile compared to HSTM. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check HSTM's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, CCLDO has a market cap of 857.3M. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while CCLDO trades at $27.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas CCLDO's P/E ratio is N/A. In terms of profitability, SNCE's ROE is -0.47%, compared to CCLDO's ROE of +0.17%. Regarding short-term risk, SNCE is more volatile compared to CCLDO. This indicates higher risk in terms of short-term price fluctuations for SNCE.Check CCLDO's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, PHR has a market cap of 734.3M. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while PHR trades at $11.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas PHR's P/E ratio is 42.43. In terms of profitability, SNCE's ROE is -0.47%, compared to PHR's ROE of +0.03%. Regarding short-term risk, SNCE is less volatile compared to PHR. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check PHR's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, SOPH has a market cap of 694.7M. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while SOPH trades at $8.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas SOPH's P/E ratio is -7.46. In terms of profitability, SNCE's ROE is -0.47%, compared to SOPH's ROE of -1.37%. Regarding short-term risk, SNCE is less volatile compared to SOPH. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check SOPH's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, CTEV has a market cap of 685.8M. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while CTEV trades at $40.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas CTEV's P/E ratio is -2.37. In terms of profitability, SNCE's ROE is -0.47%, compared to CTEV's ROE of +1.40%. Regarding short-term risk, SNCE is less volatile compared to CTEV. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check CTEV's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, MPLN-WT has a market cap of 625.2M. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while MPLN-WT trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas MPLN-WT's P/E ratio is N/A. In terms of profitability, SNCE's ROE is -0.47%, compared to MPLN-WT's ROE of +1.40%. Regarding short-term risk, SNCE is less volatile compared to MPLN-WT. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check MPLN-WT's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, ACCD has a market cap of 575.6M. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while ACCD trades at $7.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas ACCD's P/E ratio is -3.08. In terms of profitability, SNCE's ROE is -0.47%, compared to ACCD's ROE of -0.22%. Regarding short-term risk, SNCE is more volatile compared to ACCD. This indicates higher risk in terms of short-term price fluctuations for SNCE.Check ACCD's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, SHCR has a market cap of 531.8M. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while SHCR trades at $1.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas SHCR's P/E ratio is -3.76. In terms of profitability, SNCE's ROE is -0.47%, compared to SHCR's ROE of -0.25%. Regarding short-term risk, SNCE is less volatile compared to SHCR. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check SHCR's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, EVH has a market cap of 475.2M. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while EVH trades at $4.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas EVH's P/E ratio is 32.50. In terms of profitability, SNCE's ROE is -0.47%, compared to EVH's ROE of -0.99%. Regarding short-term risk, SNCE is less volatile compared to EVH. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check EVH's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, NRC has a market cap of 451M. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while NRC trades at $20.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas NRC's P/E ratio is 24.40. In terms of profitability, SNCE's ROE is -0.47%, compared to NRC's ROE of +0.48%. Regarding short-term risk, SNCE is less volatile compared to NRC. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check NRC's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, SLGC has a market cap of 396.2M. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while SLGC trades at $2.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas SLGC's P/E ratio is -3.04. In terms of profitability, SNCE's ROE is -0.47%, compared to SLGC's ROE of -0.19%. Regarding short-term risk, SNCE is less volatile compared to SLGC. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check SLGC's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, SLGCW has a market cap of 396.2M. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while SLGCW trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas SLGCW's P/E ratio is -0.16. In terms of profitability, SNCE's ROE is -0.47%, compared to SLGCW's ROE of -0.19%. Regarding short-term risk, SNCE is less volatile compared to SLGCW. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check SLGCW's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, TBRG has a market cap of 393.6M. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while TBRG trades at $26.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas TBRG's P/E ratio is 9.37. In terms of profitability, SNCE's ROE is -0.47%, compared to TBRG's ROE of +0.02%. Regarding short-term risk, SNCE is more volatile compared to TBRG. This indicates higher risk in terms of short-term price fluctuations for SNCE.Check TBRG's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, MPLN has a market cap of 375M. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while MPLN trades at $23.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas MPLN's P/E ratio is -0.23. In terms of profitability, SNCE's ROE is -0.47%, compared to MPLN's ROE of +1.40%. Regarding short-term risk, SNCE is less volatile compared to MPLN. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check MPLN's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, SY has a market cap of 370M. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while SY trades at $2.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas SY's P/E ratio is -8.55. In terms of profitability, SNCE's ROE is -0.47%, compared to SY's ROE of -0.16%. Regarding short-term risk, SNCE is less volatile compared to SY. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check SY's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, TRHC has a market cap of 284M. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while TRHC trades at $10.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas TRHC's P/E ratio is -4.27. In terms of profitability, SNCE's ROE is -0.47%, compared to TRHC's ROE of +121.31%. Regarding short-term risk, SNCE is less volatile compared to TRHC. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check TRHC's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, SMFR has a market cap of 246.4M. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while SMFR trades at $0.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas SMFR's P/E ratio is N/A. In terms of profitability, SNCE's ROE is -0.47%, compared to SMFR's ROE of -0.39%. Regarding short-term risk, SNCE is less volatile compared to SMFR. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check SMFR's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, SPOK has a market cap of 220.6M. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while SPOK trades at $10.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas SPOK's P/E ratio is 17.60. In terms of profitability, SNCE's ROE is -0.47%, compared to SPOK's ROE of +0.09%. Regarding short-term risk, SNCE is less volatile compared to SPOK. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check SPOK's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, AMWL has a market cap of 218.2M. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while AMWL trades at $12.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas AMWL's P/E ratio is -2.90. In terms of profitability, SNCE's ROE is -0.47%, compared to AMWL's ROE of -0.33%. Regarding short-term risk, SNCE is less volatile compared to AMWL. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check AMWL's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, LFMDP has a market cap of 160.2M. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while LFMDP trades at $23.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas LFMDP's P/E ratio is -724.19. In terms of profitability, SNCE's ROE is -0.47%, compared to LFMDP's ROE of -1.79%. Regarding short-term risk, SNCE is less volatile compared to LFMDP. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check LFMDP's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, OPRX has a market cap of 150.9M. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while OPRX trades at $8.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas OPRX's P/E ratio is 7.38. In terms of profitability, SNCE's ROE is -0.47%, compared to OPRX's ROE of +0.04%. Regarding short-term risk, SNCE is less volatile compared to OPRX. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check OPRX's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, LFMD has a market cap of 148.5M. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while LFMD trades at $3.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas LFMD's P/E ratio is -6.14. In terms of profitability, SNCE's ROE is -0.47%, compared to LFMD's ROE of -1.79%. Regarding short-term risk, SNCE is less volatile compared to LFMD. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check LFMD's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, CPSI has a market cap of 133.7M. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while CPSI trades at $9.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas CPSI's P/E ratio is -183.80. In terms of profitability, SNCE's ROE is -0.47%, compared to CPSI's ROE of +0.02%. Regarding short-term risk, SNCE is less volatile compared to CPSI. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check CPSI's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, HCAT has a market cap of 124.9M. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while HCAT trades at $1.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas HCAT's P/E ratio is 8.45. In terms of profitability, SNCE's ROE is -0.47%, compared to HCAT's ROE of -1.30%. Regarding short-term risk, SNCE is less volatile compared to HCAT. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check HCAT's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, AUGX has a market cap of 115.9M. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while AUGX trades at $2.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas AUGX's P/E ratio is -4.99. In terms of profitability, SNCE's ROE is -0.47%, compared to AUGX's ROE of -1.55%. Regarding short-term risk, SNCE is less volatile compared to AUGX. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check AUGX's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, DH has a market cap of 109.7M. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while DH trades at $1.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas DH's P/E ratio is 4.00. In terms of profitability, SNCE's ROE is -0.47%, compared to DH's ROE of -0.79%. Regarding short-term risk, SNCE is less volatile compared to DH. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check DH's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, CCLD has a market cap of 95.2M. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while CCLD trades at $2.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas CCLD's P/E ratio is 8.62. In terms of profitability, SNCE's ROE is -0.47%, compared to CCLD's ROE of +0.17%. Regarding short-term risk, SNCE is less volatile compared to CCLD. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check CCLD's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, WORX has a market cap of 88M. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while WORX trades at $5.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas WORX's P/E ratio is -6.40. In terms of profitability, SNCE's ROE is -0.47%, compared to WORX's ROE of -0.35%. Regarding short-term risk, SNCE is less volatile compared to WORX. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check WORX's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, FORA has a market cap of 67.8M. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while FORA trades at $2.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas FORA's P/E ratio is -24.11. In terms of profitability, SNCE's ROE is -0.47%, compared to FORA's ROE of -0.17%. Regarding short-term risk, SNCE is more volatile compared to FORA. This indicates higher risk in terms of short-term price fluctuations for SNCE.Check FORA's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, CCLDP has a market cap of 59.9M. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while CCLDP trades at $19.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas CCLDP's P/E ratio is N/A. In terms of profitability, SNCE's ROE is -0.47%, compared to CCLDP's ROE of +0.17%. Regarding short-term risk, SNCE is less volatile compared to CCLDP. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check CCLDP's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, AKLI has a market cap of 34.1M. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while AKLI trades at $0.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas AKLI's P/E ratio is -0.71. In terms of profitability, SNCE's ROE is -0.47%, compared to AKLI's ROE of -0.70%. Regarding short-term risk, SNCE is less volatile compared to AKLI. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check AKLI's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, SHLT has a market cap of 33.6M. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while SHLT trades at $2.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas SHLT's P/E ratio is -3.87. In terms of profitability, SNCE's ROE is -0.47%, compared to SHLT's ROE of -0.50%. Regarding short-term risk, SNCE is more volatile compared to SHLT. This indicates higher risk in terms of short-term price fluctuations for SNCE.Check SHLT's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, ONMD has a market cap of 32.9M. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while ONMD trades at $0.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas ONMD's P/E ratio is -3.61. In terms of profitability, SNCE's ROE is -0.47%, compared to ONMD's ROE of +2.35%. Regarding short-term risk, SNCE is less volatile compared to ONMD. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check ONMD's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, SHCRW has a market cap of 32.5M. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while SHCRW trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas SHCRW's P/E ratio is -0.00. In terms of profitability, SNCE's ROE is -0.47%, compared to SHCRW's ROE of -0.25%. Regarding short-term risk, SNCE is less volatile compared to SHCRW. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check SHCRW's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, ONMDW has a market cap of 30.2M. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while ONMDW trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas ONMDW's P/E ratio is N/A. In terms of profitability, SNCE's ROE is -0.47%, compared to ONMDW's ROE of +2.35%. Regarding short-term risk, SNCE is less volatile compared to ONMDW. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check ONMDW's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, STRM has a market cap of 23.2M. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while STRM trades at $5.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas STRM's P/E ratio is -2.40. In terms of profitability, SNCE's ROE is -0.47%, compared to STRM's ROE of -0.65%. Regarding short-term risk, SNCE is more volatile compared to STRM. This indicates higher risk in terms of short-term price fluctuations for SNCE.Check STRM's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, RNLX has a market cap of 22.5M. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while RNLX trades at $0.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas RNLX's P/E ratio is -0.33. In terms of profitability, SNCE's ROE is -0.47%, compared to RNLX's ROE of -6.31%. Regarding short-term risk, SNCE is less volatile compared to RNLX. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check RNLX's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, LIFW has a market cap of 22.4M. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while LIFW trades at $3.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas LIFW's P/E ratio is -0.02. In terms of profitability, SNCE's ROE is -0.47%, compared to LIFW's ROE of +1.56%. Regarding short-term risk, SNCE is more volatile compared to LIFW. This indicates higher risk in terms of short-term price fluctuations for SNCE.Check LIFW's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, BBLN has a market cap of 14.1M. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while BBLN trades at $0.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas BBLN's P/E ratio is -0.04. In terms of profitability, SNCE's ROE is -0.47%, compared to BBLN's ROE of +4.89%. Regarding short-term risk, SNCE is less volatile compared to BBLN. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check BBLN's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, ETAO has a market cap of 9.8M. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while ETAO trades at $1.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas ETAO's P/E ratio is -0.01. In terms of profitability, SNCE's ROE is -0.47%, compared to ETAO's ROE of -13.69%. Regarding short-term risk, SNCE is less volatile compared to ETAO. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check ETAO's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, BFRG has a market cap of 9.1M. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while BFRG trades at $0.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas BFRG's P/E ratio is -1.07. In terms of profitability, SNCE's ROE is -0.47%, compared to BFRG's ROE of -1.50%. Regarding short-term risk, SNCE is less volatile compared to BFRG. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check BFRG's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, MGRX has a market cap of 6.5M. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while MGRX trades at $0.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas MGRX's P/E ratio is -0.28. In terms of profitability, SNCE's ROE is -0.47%, compared to MGRX's ROE of -1.06%. Regarding short-term risk, SNCE is less volatile compared to MGRX. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check MGRX's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, UPH-WT has a market cap of 5.3M. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while UPH-WT trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas UPH-WT's P/E ratio is N/A. In terms of profitability, SNCE's ROE is -0.47%, compared to UPH-WT's ROE of -1.05%. Regarding short-term risk, SNCE is less volatile compared to UPH-WT. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check UPH-WT's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, UPH has a market cap of 5.3M. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while UPH trades at $0.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas UPH's P/E ratio is -0.07. In terms of profitability, SNCE's ROE is -0.47%, compared to UPH's ROE of -1.05%. Regarding short-term risk, SNCE is less volatile compared to UPH. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check UPH's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, PEARW has a market cap of 4.1M. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while PEARW trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas PEARW's P/E ratio is -0.00. In terms of profitability, SNCE's ROE is -0.47%, compared to PEARW's ROE of -0.39%. Regarding short-term risk, SNCE is less volatile compared to PEARW. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check PEARW's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, PEAR has a market cap of 4.1M. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while PEAR trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas PEAR's P/E ratio is -0.08. In terms of profitability, SNCE's ROE is -0.47%, compared to PEAR's ROE of -0.39%. Regarding short-term risk, SNCE is less volatile compared to PEAR. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check PEAR's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, OTRK has a market cap of 2.3M. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while OTRK trades at $0.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas OTRK's P/E ratio is -0.02. In terms of profitability, SNCE's ROE is -0.47%, compared to OTRK's ROE of -2.11%. Regarding short-term risk, SNCE is more volatile compared to OTRK. This indicates higher risk in terms of short-term price fluctuations for SNCE.Check OTRK's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, CMAX has a market cap of 1.6M. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while CMAX trades at $0.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas CMAX's P/E ratio is -0.00. In terms of profitability, SNCE's ROE is -0.47%, compared to CMAX's ROE of -2.01%. Regarding short-term risk, SNCE is more volatile compared to CMAX. This indicates higher risk in terms of short-term price fluctuations for SNCE.Check CMAX's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, BFRGW has a market cap of 1.4M. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while BFRGW trades at $0.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas BFRGW's P/E ratio is -0.92. In terms of profitability, SNCE's ROE is -0.47%, compared to BFRGW's ROE of -1.50%. Regarding short-term risk, SNCE is less volatile compared to BFRGW. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check BFRGW's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, LIFWZ has a market cap of 1.3M. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while LIFWZ trades at $0.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas LIFWZ's P/E ratio is N/A. In terms of profitability, SNCE's ROE is -0.47%, compared to LIFWZ's ROE of +1.56%. Regarding short-term risk, SNCE is more volatile compared to LIFWZ. This indicates higher risk in terms of short-term price fluctuations for SNCE.Check LIFWZ's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, ACON has a market cap of 1.2M. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while ACON trades at $2.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas ACON's P/E ratio is -0.26. In terms of profitability, SNCE's ROE is -0.47%, compared to ACON's ROE of -0.59%. Regarding short-term risk, SNCE is less volatile compared to ACON. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check ACON's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, HCTI has a market cap of 947.8K. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while HCTI trades at $0.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas HCTI's P/E ratio is -0.10. In terms of profitability, SNCE's ROE is -0.47%, compared to HCTI's ROE of -0.56%. Regarding short-term risk, SNCE is less volatile compared to HCTI. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check HCTI's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, VSEEW has a market cap of 560.3K. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while VSEEW trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas VSEEW's P/E ratio is -0.04. In terms of profitability, SNCE's ROE is -0.47%, compared to VSEEW's ROE of -4.01%. Regarding short-term risk, SNCE is less volatile compared to VSEEW. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check VSEEW's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, MSPRZ has a market cap of 550.4K. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while MSPRZ trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas MSPRZ's P/E ratio is N/A. In terms of profitability, SNCE's ROE is -0.47%, compared to MSPRZ's ROE of +1.56%. Regarding short-term risk, SNCE is less volatile compared to MSPRZ. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check MSPRZ's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, VSEE has a market cap of 274.9K. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while VSEE trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas VSEE's P/E ratio is -0.04. In terms of profitability, SNCE's ROE is -0.47%, compared to VSEE's ROE of -4.01%. Regarding short-term risk, SNCE is less volatile compared to VSEE. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check VSEE's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, KERN has a market cap of 162.3K. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while KERN trades at $0.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas KERN's P/E ratio is -0.01. In terms of profitability, SNCE's ROE is -0.47%, compared to KERN's ROE of -0.20%. Regarding short-term risk, SNCE is less volatile compared to KERN. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check KERN's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, KERNW has a market cap of 162.3K. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while KERNW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas KERNW's P/E ratio is -0.00. In terms of profitability, SNCE's ROE is -0.47%, compared to KERNW's ROE of -0.20%. Regarding short-term risk, SNCE is less volatile compared to KERNW. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check KERNW's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, LIFWW has a market cap of 60.1K. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while LIFWW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas LIFWW's P/E ratio is N/A. In terms of profitability, SNCE's ROE is -0.47%, compared to LIFWW's ROE of +1.56%. Regarding short-term risk, SNCE is more volatile compared to LIFWW. This indicates higher risk in terms of short-term price fluctuations for SNCE.Check LIFWW's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, CMAXW has a market cap of 36.4K. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while CMAXW trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas CMAXW's P/E ratio is N/A. In terms of profitability, SNCE's ROE is -0.47%, compared to CMAXW's ROE of -2.01%. Regarding short-term risk, SNCE is more volatile compared to CMAXW. This indicates higher risk in terms of short-term price fluctuations for SNCE.Check CMAXW's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, ZCMD has a market cap of 31.2K. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while ZCMD trades at $0.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas ZCMD's P/E ratio is -0.03. In terms of profitability, SNCE's ROE is -0.47%, compared to ZCMD's ROE of -0.32%. Regarding short-term risk, SNCE is less volatile compared to ZCMD. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check ZCMD's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, ACONW has a market cap of 18.7K. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while ACONW trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas ACONW's P/E ratio is N/A. In terms of profitability, SNCE's ROE is -0.47%, compared to ACONW's ROE of -0.59%. Regarding short-term risk, SNCE is less volatile compared to ACONW. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check ACONW's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, CHNGU has a market cap of 0. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while CHNGU trades at $73.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas CHNGU's P/E ratio is N/A. In terms of profitability, SNCE's ROE is -0.47%, compared to CHNGU's ROE of -0.05%. Regarding short-term risk, SNCE is less volatile compared to CHNGU. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check CHNGU's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, IMS has a market cap of 0. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while IMS trades at $31.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas IMS's P/E ratio is N/A. In terms of profitability, SNCE's ROE is -0.47%, compared to IMS's ROE of +0.27%. Regarding short-term risk, SNCE is less volatile compared to IMS. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check IMS's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, CERN has a market cap of 0. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while CERN trades at $94.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas CERN's P/E ratio is 55.84. In terms of profitability, SNCE's ROE is -0.47%, compared to CERN's ROE of +0.14%. Regarding short-term risk, SNCE is more volatile compared to CERN. This indicates higher risk in terms of short-term price fluctuations for SNCE.Check CERN's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, AFFX has a market cap of 0. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while AFFX trades at $14.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas AFFX's P/E ratio is N/A. In terms of profitability, SNCE's ROE is -0.47%, compared to AFFX's ROE of +0.03%. Regarding short-term risk, SNCE is less volatile compared to AFFX. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check AFFX's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, MSPRV has a market cap of 0. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while MSPRV trades at $0.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas MSPRV's P/E ratio is N/A. In terms of profitability, SNCE's ROE is -0.47%, compared to MSPRV's ROE of N/A. Regarding short-term risk, SNCE is less volatile compared to MSPRV. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check MSPRV's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, MTBC has a market cap of 0. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while MTBC trades at $3.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas MTBC's P/E ratio is N/A. In terms of profitability, SNCE's ROE is -0.47%, compared to MTBC's ROE of +0.19%. Regarding short-term risk, SNCE is less volatile compared to MTBC. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check MTBC's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, MTBCO has a market cap of 0. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while MTBCO trades at $25.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas MTBCO's P/E ratio is N/A. In terms of profitability, SNCE's ROE is -0.47%, compared to MTBCO's ROE of +0.17%. Regarding short-term risk, SNCE is more volatile compared to MTBCO. This indicates higher risk in terms of short-term price fluctuations for SNCE.Check MTBCO's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, MTBCP has a market cap of 0. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while MTBCP trades at $26.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas MTBCP's P/E ratio is N/A. In terms of profitability, SNCE's ROE is -0.47%, compared to MTBCP's ROE of +0.17%. Regarding short-term risk, SNCE is less volatile compared to MTBCP. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check MTBCP's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, CNVY has a market cap of 0. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while CNVY trades at $10.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas CNVY's P/E ratio is -71.50. In terms of profitability, SNCE's ROE is -0.47%, compared to CNVY's ROE of -0.02%. Regarding short-term risk, SNCE is less volatile compared to CNVY. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check CNVY's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, NH has a market cap of 0. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while NH trades at $1.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas NH's P/E ratio is -0.12. In terms of profitability, SNCE's ROE is -0.47%, compared to NH's ROE of +0.35%. Regarding short-term risk, SNCE is less volatile compared to NH. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check NH's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, KURIU has a market cap of 0. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while KURIU trades at $9.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas KURIU's P/E ratio is N/A. In terms of profitability, SNCE's ROE is -0.47%, compared to KURIU's ROE of +1.06%. Regarding short-term risk, SNCE is less volatile compared to KURIU. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check KURIU's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, SMFRW has a market cap of 0. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while SMFRW trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas SMFRW's P/E ratio is N/A. In terms of profitability, SNCE's ROE is -0.47%, compared to SMFRW's ROE of -0.39%. Regarding short-term risk, SNCE is less volatile compared to SMFRW. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check SMFRW's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, CHNG has a market cap of 0. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while CHNG trades at $27.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas CHNG's P/E ratio is -152.72. In terms of profitability, SNCE's ROE is -0.47%, compared to CHNG's ROE of -0.05%. Regarding short-term risk, SNCE is less volatile compared to CHNG. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check CHNG's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, CSLT has a market cap of 0. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while CSLT trades at $2.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas CSLT's P/E ratio is -37.27. In terms of profitability, SNCE's ROE is -0.47%, compared to CSLT's ROE of -0.42%. Regarding short-term risk, SNCE is less volatile compared to CSLT. This indicates lower risk in terms of short-term price fluctuations for SNCE.Check CSLT's competition here

Science 37 Holdings, Inc. (NASDAQ: SNCE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNCE stands at 34.7M. In comparison, NAVA has a market cap of 0. Regarding current trading prices, SNCE is priced at $5.75 on the NASDAQ, while NAVA trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNCE currently has a P/E ratio of -0.27, whereas NAVA's P/E ratio is N/A. In terms of profitability, SNCE's ROE is -0.47%, compared to NAVA's ROE of +0.15%. Regarding short-term risk, SNCE is not fully comparable compared to NAVA. This indicates unavailable risk data in terms of short-term price fluctuations for SNCE.Check NAVA's competition here